Immunohistological Characterization of Myeloid and Leukemia-Associated Monoclonal Antibodies

Horton, Michael A.; Lewis, D.; McNulty, Katrina

doi:10.1007/978-1-4612-4850-7_21

Cited by 4 publications

(4 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our non-haemopoietic reactivity data is generally similar to findings from previous studies (Hancock et al, 1984;Pulford et al, 1984;Horton et al, 1985Horton et al, , 1986Franklin et al, 1987: Berti et a/, 1986. One exception is the finding of Horton et al (1986) reporting reactivity ofL4F3 (CD-33) with interstitial cells and endothelium of adult kidney, which we were unable to confirm.…”

Section: Discussionsupporting

confidence: 92%

“…Expressed only weakly on mature myeloid bone marrow cells, the CD-33 antigen is detectable on virtually all myeloid progenitor cells including CFUgm. BFUe and CFUgemm (Griffin et al, 1984;Andrews et al, 1983Andrews et al, , 1984Dinnorf et al, 1986;Janowska-Weiczorek et al, 1986;Peschel et al, 1986;Alonso et al 1986;Berti et al, 1986Berti et al, , 1987Hancock et al, 1986;Horton et al, 1986;Favaloro et al, 1987).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non‐haemopoietic distribution using panels of monoclonal antibodies belonging to CD‐11b, CD‐13 and CD‐33

et al. 1988

View full text Add to dashboard Cite

We have investigated the binding of over 30 different monoclonal antibodies (MAB) belonging to three distinct clusters of differentiation (CD-11b; CD-13; CD-33; as defined by the Third International Workshop on Leucocyte Differentiation Antigens (ILWS), 1986), and which are reactive with three distinct myeloid restricted surface antigens ('gp160,95'; 'gp150'; 'gp67'). By investigating reactivity with non-haemopoietic cells, we have confirmed that CD-11b and CD-33 MAB reactivity is largely restricted to haemopoietic cells, whilst CD-13 MAB showed additional binding to a wide range of non-haemopoietic cells. Epitopic heterogeneity was also investigated within each cluster of differentiation. Tested anti-CR3 (CD-11b) MAB varied in their ability to block the binding of complement coated sheep red blood cells and zymosan particles. A more detailed analysis of MAB binding heterogeneity was performed by competitive inhibition assays. It was demonstrated that MAB from both CD-11b and CD-13 bind to several distinct epitopes (at least six and five respectively) on their respective antigen molecules. In contrast, CD-33 MAB appear to bind to only a single site on 'gp67'. These data may allow for a clearer appreciation of the disparate functional effects obtained using different MAB reagents to individual myeloid antigens, as reported by a number of workers.

show abstract

Section: Discussionsupporting

confidence: 92%

mentioning

confidence: 99%

Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non‐haemopoietic distribution using panels of monoclonal antibodies belonging to CD‐11b, CD‐13 and CD‐33

et al. 1988

View full text Add to dashboard Cite

show abstract

“…β2 integrins are expressed on most types of white blood cells where they play a role in leukocyte-leukocyte and leukocyte-endothelium interactions. This includes germinal center B cells in lymphoid follicles [19]; [20], homing of blood lymphocytes into lymphoid tissues, binding of B cells to follicular dendritic cells, adhesion of cytotoxic T cells to their target cells, mixed lymphocyte reactions, antigen-specific and CD3-induced T cell proliferation either in naïve or in memory/effector T helper cells [21] and the T cell-dependent antibody response [22][23][24]. Although integrins are involved in processes like inflammation, cellular growth, differentiation, junction formation and polarity, it is conceivable that the deficiency of accessory adhesion molecules could lead to enhancement of the spread of neoplastic cells [25][26][27].…”

Section: Discussionmentioning

confidence: 99%

CD18 deficiency evolving to megakaryocytic (M7) acute myeloid leukemia: Case report

Vasconcelos

Beitler

Martinez

et al. 2014

Blood Cells, Molecules, and Diseases

View full text Add to dashboard Cite

“…However, these cells acquire an LCL-phenotype when transformed with EBV (data not shown). In addition, antibodies to CDllaKD18 have been reported to have a pan-reactivity with tonsil sections (Horton et al, 1986). Both LCLs and BL lines are activated and proliferating cells.…”

Section: E L a T I V E F L U O R E S C E N C E I N T E N S I T Y ( L mentioning

confidence: 99%

Absence, or low expression, of leukocyte adhesion molecules CDI1 and CD18 on burkjtt lymphoma cells

Patarroyo

Prieto

Ernberg

et al. 1988

Intl Journal of Cancer

View full text Add to dashboard Cite

Leukocyte adhesion to cells is mediated by the cell-surface glycoprotein complex CD11a-c/CD18 and, in some cases, the glycoprotein gp84. The process is associated with leukocyte activation and modulates lymphocyte proliferation and maturation. Epstein-Barr virus (EBV)-transformed normal B lymphocytes give rise to lymphoblastoid cell lines (LCLs) which grow as large clusters mediated by adhesion molecules. In contrast, newly explanted EBV-infected Burkitt lymphoma (BL) cells usually grow as single cells or as loose clusters. We now report that EBV positive- and EBV-negative BL lines lack the adhesive protein complex, or have only low levels of it, whereas LCLs, representing various stages of B-lymphocyte development, contain considerably higher amounts, as measured by immunofluorescence flow cytometry and immunoprecipitation. The level of gp84 expression is of the same magnitude in both types of cells.

show abstract

Immunohistological Characterization of Myeloid and Leukemia-Associated Monoclonal Antibodies

Cited by 4 publications

References 2 publications

Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non‐haemopoietic distribution using panels of monoclonal antibodies belonging to CD‐11b, CD‐13 and CD‐33

Further characterization of human myeloid antigens (gp160,95; gp150; gp67): investigation of epitopic heterogeneity and non‐haemopoietic distribution using panels of monoclonal antibodies belonging to CD‐11b, CD‐13 and CD‐33

CD18 deficiency evolving to megakaryocytic (M7) acute myeloid leukemia: Case report

Absence, or low expression, of leukocyte adhesion molecules CDI1 and CD18 on burkjtt lymphoma cells

Contact Info

Product

Resources

About